12 recruiting, 1 active not recruiting. 8 Phase 2, 4 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Recruiting 8 |
| Phase 3 | 4 | Recruiting 4 |
| Phase 1 | 1 | Active not recruiting 1 |
Follow Brenipatide: new trials by email Literature Review of Brenipatide trials Research Report on Brenipatide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder Brenipatide, Placebo - Depressive Disorder, Major | Phase 3 | Recruiting | Eli Lilly and Company | 1000 | 2026-08-14 | 2026-10-07 |
| A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) Brenipatide, Placebo, Standard of Care - Pulmonary Disease, Chronic Obstructive | Phase 2 | Recruiting | Eli Lilly and Company | 606 | 2026-08-07 | 2026-10-08 |
| A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D) LY3537031, Placebo - Irritable Bowel Syndrome, Diarrhea | Phase 2 | Recruiting | Eli Lilly and Company | 531 | 2026-05-06 | 2026-10-08 |
| A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C) LY3537031, Placebo - Irritable Bowel Syndrome, Constipation | Phase 2 | Recruiting | Eli Lilly and Company | 342 | 2026-04-29 | 2026-10-08 |
| A Study of Brenipatide (LY3537031) in Healthy Participants With Overweight or Obesity Brenipatide, Placebo - Obesity, Overweight | Phase 1 | Active not recruiting | Eli Lilly and Company | 150 | 2026-03-18 | 2026-07-16 |
| A Study of Brenipatide in Participants With Opioid Use Disorder Brenipatide, Placebo, Buprenorphine - Opioid Use Disorder | Phase 2 | Recruiting | Eli Lilly and Company | 465 | 2026-02-13 | 2026-10-07 |
| A Study of Brenipatide in Adult Participants With Schizophrenia Brenipatide, Placebo - Schizophrenia | Phase 2 | Recruiting | Eli Lilly and Company | 450 | 2026-02-10 | 2026-10-07 |
| A Study of Brenipatide in Adult Participants With Major Depressive Disorder Brenipatide, Placebo - Depressive Disorder, Major | Phase 3 | Recruiting | Eli Lilly and Company | 1000 | 2026-02-09 | 2026-10-05 |
| A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1) Brenipatide, Placebo - Bipolar Disorder | Phase 2 | Recruiting | Eli Lilly and Company | 400 | 2025-11-24 | 2026-10-07 |
| A Study of Brenipatide in Adults Who Quit Smoking Cigarettes and Want to Avoid Relapse Brenipatide, Placebo - Smoking | Phase 2 | Recruiting | Eli Lilly and Company | 222 | 2025-11-03 | 2026-09-22 |
| A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma Brenipatide, Placebo - Asthma | Phase 2 | Recruiting | Eli Lilly and Company | 531 | 2025-10-22 | 2026-10-22 |
| A Study of Brenipatide in Participants With Alcohol Use Disorder LY3537031, Placebo - Alcohol Use Disorder | Phase 3 | Recruiting | Eli Lilly and Company | 1100 | 2025-10-16 | 2026-10-08 |
| A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder LY3537031, Placebo - Alcohol Use Disorder | Phase 3 | Recruiting | Eli Lilly and Company | 1100 | 2025-10-15 | 2026-10-07 |
Alcoholism (2) · Depression (2) · Depressive Disorder (2) · Depressive Disorder, Major (2) · Irritable Bowel Syndrome (2) · Mood Disorders (2) · Asthma (1) · Bipolar Disorder (1) · Bronchitis, Chronic (1) · Constipation (1) · Diarrhea (1) · Emphysema (1) · Lung Diseases (1) · Obesity (1) · Opioid-Related Disorders (1)
United States (13) · China (11) · Japan (11) · United Kingdom (8) · Canada (7) · Germany (7) · Mexico (7) · Brazil (5) · Poland (5) · Puerto Rico (5) · South Korea (5) · Taiwan (5) · Argentina (4) · Belgium (4) · India (4)
2025 (7)